Literature DB >> 28544788

Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality.

Julie J Paik1, Fredrick M Wigley1, Ami A Shah1, Andrea M Corse1, Livia Casciola-Rosen1, Laura K Hummers1, Andrew L Mammen2.   

Abstract

OBJECTIVE: To determine if a unique subtype of scleroderma muscle disease exists by comparing the clinical features of systemic sclerosis (SSc; scleroderma) patients with predominant fibrosis on muscle biopsy to those with inflammatory muscle histopathology.
METHODS: This retrospective, cross-sectional study included SSc patients with muscle weakness and an available muscle biopsy. Biopsies with fibrosis but without inflammation/necrosis were designated as "fibrosing myopathy," and those with inflammation and/or necrosis were assigned a category of "inflammatory myopathy." Clinical data, including features of SSc, serum creatine kinase (CK) levels, electromyography, autoantibody profile, and survival, were compared between the 2 groups.
RESULTS: The study population consisted of 37 weak SSc patients, 8 with fibrosing myopathy and 29 with inflammatory myopathy. Compared to those with inflammatory myopathy, patients with fibrosing myopathy were more likely to have diffuse SSc skin subtype (87% versus 62%; P = 0.18), African American race (62.5% versus 37.9%; P = 0.20), and a lower mean ± SD forced vital capacity (55.5 ± 31.9 versus 66.4 ± 17.6; P = 0.23). They also had lower mean ± SD CK values (516 ± 391 versus 2,477 ± 3,511 IU/liter; P = 0.007) and lower aldolase values (13.8 ± 4.7 versus 27.3 ± 4.7; P = 0.01). Patients with fibrosing myopathy had a significantly higher mortality (5 of 8 [62.5%] versus 4 of 29 [14.3%]; P = 0.005).
CONCLUSION: Fibrosing myopathy is a unique histologic subtype of muscle disease among weak patients with SSc and is associated with significantly worse mortality compared to those with inflammation and/or necrosis on muscle biopsy.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 28544788      PMCID: PMC5791890          DOI: 10.1002/acr.23291

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  14 in total

1.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

2.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

3.  Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association.

Authors:  W P Follansbee; T R Zerbe; T A Medsger
Journal:  Am Heart J       Date:  1993-01       Impact factor: 4.749

Review 4.  The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review.

Authors:  Chayawee Muangchan; Murray Baron; Janet Pope
Journal:  J Rheumatol       Date:  2013-07-15       Impact factor: 4.666

5.  A disease severity scale for systemic sclerosis: development and testing.

Authors:  T A Medsger; A J Silman; V D Steen; C M Black; A Akesson; P A Bacon; C A Harris; S Jablonska; M I Jayson; S A Jimenez; T Krieg; E C Leroy; P J Maddison; M L Russell; R K Schachter; F A Wollheim; H Zacharaie
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

6.  Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness.

Authors:  Julie J Paik; Fredrick M Wigley; Thomas E Lloyd; Andrea M Corse; Livia Casciola-Rosen; Ami A Shah; Francesco Boin; Laura K Hummers; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

7.  Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations.

Authors:  P J Clements; D E Furst; D S Campion; A Bohan; R Harris; J Levy; H E Paulus
Journal:  Arthritis Rheum       Date:  1978 Jan-Feb

8.  Skeletal muscle involvement in progressive systemic sclerosis (scleroderma).

Authors:  T A Medsger; G P Rodnan; J Moossy; J W Vester
Journal:  Arthritis Rheum       Date:  1968-08

9.  Independent Association of Severity of Muscle Weakness With Disability as Measured by the Health Assessment Questionnaire Disability Index in Scleroderma.

Authors:  Julie J Paik; Fredrick M Wigley; Amanda F Mejia; Laura K Hummers
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-10-09       Impact factor: 4.794

10.  Anti-U3 RNP autoantibodies in systemic sclerosis.

Authors:  Rohit Aggarwal; Mary Lucas; Noreen Fertig; Chester V Oddis; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2009-04
View more
  8 in total

1.  The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus.

Authors:  John D Pauling; Sarah Skeoch; Julie J Paik
Journal:  Indian J Rheumatol       Date:  2021-01-18

2.  Persistent eosinophilia and associated organ involvement in Thai patients with systemic sclerosis: Data from the Siriraj scleroderma cohort.

Authors:  Somsak Punjasamanvong; Chayawee Muangchan
Journal:  Arch Rheumatol       Date:  2021-10-18       Impact factor: 1.472

3.  Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis.

Authors:  André La Gerche; Mandana Nikpour; Laura Ross; Anniina Lindqvist; Benedict Costello; Dylan Hansen; Zoe Brown; Jessica A Day; Wendy Stevens; Andrew Burns; Warren Perera; Marcus Pianta
Journal:  Arthritis Res Ther       Date:  2022-04-11       Impact factor: 5.156

Review 4.  The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.

Authors:  Nicola Farina; Giovanni Benanti; Giacomo De Luca; Anna Palmisano; Giovanni Peretto; Sara Tomassetti; Veronica Giorgione; Ornella Forma; Antonio Esposito; Silvio Danese; Lorenzo Dagna; Marco Matucci-Cerinic; Corrado Campochiaro
Journal:  J Multidiscip Healthc       Date:  2022-04-20

Review 5.  Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.

Authors:  Chiara Bellocchi; Augustine Chung; Elizabeth R Volkmann
Journal:  Open Access Rheumatol       Date:  2022-09-15

Review 6.  The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.

Authors:  Ioana Bratoiu; Alexandra Maria Burlui; Anca Cardoneanu; Luana Andreea Macovei; Patricia Richter; Gabriela Rusu-Zota; Ciprian Rezus; Minerva Codruta Badescu; Andreea Szalontay; Elena Rezus
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

7.  Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies.

Authors:  Océane Landon-Cardinal; Alexandra Baril-Dionne; Sabrina Hoa; Alain Meyer; Valérie Leclair; Josiane Bourré-Tessier; Anne-Marie Mansour; Farah Zarka; Jean-Paul Makhzoum; Jessica Nehme; Eric Rich; Jean-Richard Goulet; Tamara Grodzicky; Martial Koenig; France Joyal; Isabelle Richard; Marie Hudson; Ira Targoff; Minoru Satoh; Marvin J Fritzler; Yves Troyanov; Jean-Luc Senécal
Journal:  RMD Open       Date:  2020-09

8.  Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis: A retrospective cohort study.

Authors:  Meiju Zhou; Lichun Jiang; Liuyan Nie; Ting Chen; Ting Zhang; Wenjia Sun; Joshua Sutikno; Yan Du; Jing Xue
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.